Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: May 5, 2026
Reporting Period: First quarter ended March 31, 2026
Context: The filing announces the financial results for the first quarter of 2026. The detailed results are contained in a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references the announcement of financial results but does not contain the specific numerical data within the body of this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to Exhibit 99.1 (Press Release) for comparative analysis.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the release of Q1 2026 results but does not include specific commentary, guidance, or outlook details in the main text.
Risks and Contingencies: No specific risks or contingencies are detailed in this excerpt.
Unusual Items: None identified in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 5, 2026) for actual revenue, net income, and cash flow figures.
- Verify year-over-year growth rates and margin trends in the attached press release.
- Check for updated full-year 2026 financial guidance within the press release.
- Confirm the status of key clinical trials or product launches mentioned in the full announcement.